___

• Ahren B, Pacini G. Islet adaptation to insulin resistance: mechanisms and implications for intervention. Diabetes Obes Metab 2005; 7(1): 2-8.
• Mari A, Ahren B, Pacini G. Assessment of in- sulin secretion in relation to insulin resistance. Curr Opin Clin Nutr Metab care 2005; 8(5): 529-533.
• Reaven GM. Pathophsiology of insulin resist- ance in human disease. Physiol Rev. 1995; 75(3): 473-486.
• Kim JA, Wei Y, Sowers JR. Role of mitochon- drial dysfunction in insulin resistance. Circ Res 2008; 102(4): 401-414.
• Lee SH, Park SA, Ko SH et al. Insulin resistance and inflammation may have an additional role in the link between cystatin C and cardiovascu- lar disease in type 2 diabetes mellitus patients. Metabolism 2010; 59(2): 241-246.
• Klok MD, Jakopsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev. 2007; 8(1): 21-34.
• Reaven G, Abbasi F, McLaughin T. Obesity, insulin resistance and cardiovascular disease. Recent Prog Horm Res 2004; 59: 207-223.
• Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med. 2008; 14(3-4): 222-231.
• Florez H, Castillo-Florez S, Mendez A et al. C-reactive protein is elavated in obese patients with the metabolic syndrome. Diabetes Res Clin Pract 2006; 71(1): 92-100.
• Rifai N. High-sensitivity C-reactive protein: a useful marker for cardiovascular disease risk prediction and the metabolic syndrome. Clin Chem. 2005; 51(3): 504-505.
• Semple RK, Cochran EK, Soos MA et al. Plasma adiponectin as a marker of insulin receptor dysfunction: clinical utility in severe insulin re- sistance. Diabetes Care. 2008; 31(5): 977-979.
• Moreno-Navarrete JM, Catalan V, Ortega F et al. Circulating omentin concentration increases after weight loss. Nutr Metab. 2010; 7: 27-36.
• Diamant M, Tushuizen ME. The metabolic syn- drome and endothelialdysfunction: common highway to type 2 diabetes and cardiovascular disease. Curr Diab Rep 2006; 6(4): 279-286.
• Lutsey PL, Steffen LM, Stevens J. Dietary intake and the development of the metabolic syn- drome: the Atherosclerosis Risk in Communi- ties Study. Circulation. 2008; 117(6): 754-761.
• Van Raalte DH, Brands M, Van der Zijl NJ et al. Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial. Diabetologia 2011; 54(8): 2103-2112.
• Baudrand R, Campino C, Carvajal CA et al. High sodium intake is associated with in- creased glucocorticoid production, insulin resistance and metabolic syndrome. Clin Endo- crinol 2014; 80(5): 677-684.
• DE Wit S, Sabin Ca, Weber R et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetetes Care 2008; 31(6): 1224- 1229.
• Yu IC, Lin HY, Sparks JD et al. Androgenrecep- tor roles in insulin resistance and obesity in males: the linkagee of androgen-deprivation therapy to metabolic syndrome. Diabetes 2014; 63(10): 3180-3188.
• Sarti C, Gallagher J. The metabolic syndrome prevalance, CHD risk and treatment. J Diabetes Complications 2006; 20(2): 121-132.
• Levy- Marchal C, Arslanian S, Cutfield W et al.Insulin resistance in children: consensus, perspective and future directions. J Clin Endo- crinol Metab 2010; 95(12): 5189-5198.
• Kahn R, Buse J, Ferrannini E et al. The metabol- ic syndrome: time for a critical appraisal: joint statement from the American Diabetes Asso- ciation and the European Association fort he Study of Diabetes. Diabetes Care. 2005; 28(9): 2289-2304.
• Essah PA, Nestler JE. The metabolic syndrome in polycystic ovary syndrome. J Endocrinol Invest 2006; 29(3): 270-280.
• De Taeye B, Smith LH, Vaughan DE. Plasmino- gen activator inhibitor-1: a common denom- inator in obesity, diabetes and cardiovascular disease. Curr OPin Pharmacol 2005; 5(2): 149-154.
• Sjöholm A, Nyström T. Endothelial inflamma- tion in insulin resistance. Lancet. 2005; 365 (9459): 610-612.
• Matthews DR, Hosker JP, Rudenski AS et al. Ho- meostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28(7): 412-419.
• Katz A, Nambi SS, Mather K et al. Quantitative insulin sensitivity check index: a simple, accu- rate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2008; 249(1): 15-26.
• Muniyappa R, Lee S, Chen H et al. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations and appropriate usage. Am J Physiol Endocrinol Metab 2008; 294(1): 15-26.
• Jensterle M, Janez A, Mlinar B et al.Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome. Eur J Endocrinol 2008; 158(6): 793-801.
• Salpeter SR, Buckley NS, Kahn JA et al. Me- ta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med. 2008; 121(2): 149-157.
• Quinn CE, Hamilton PK, Lockhart CJ et al. Thi- azolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol 2008; 153(4): 636-645.
• Lee WJ, Lee YC, Ser KH et al. Improvement of insulin resistance after obesity surgery: a com- parison of gastric banding and bypass proce- dures. Obes Surg 2008; 18(9): 1119-1125.
• Herman WH, Hoerger TJ, Brandle M et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005; 142(5): 323-332.
• Hawley JA, Lessard SJ. Exercise training-in- duced improvements in insulin action. Acta Physiol 2008; 192(1): 127-135.